IDEAYA Biosciences

IDEAYA Biosciences is a clinical-stage precision medicine oncology company headquartered in South San Francisco, California. The company specializes in the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics, with a primary focus on synthetic lethality, an emerging class of precision medicine targets. IDEAYA’s pipeline includes several advanced programs such as darovasertib (IDE196), a clinical-stage PKC inhibitor for genetically-defined cancers with GNAQ or GNA11 gene mutations, and IDE397, a clinical-stage MAT2A inhibitor targeting patients with tumors having MTAP gene deletion, which represents approximately 15% of solid tumors. Additionally, IDEAYA is developing IDE161, a clinical-stage PARG inhibitor for patients with tumors having homologous recombination deficiency (HRD). The company has established strategic partnerships with GlaxoSmithKline (GSK) on its Pol Theta and Werner Helicase synthetic lethality programs, with Pfizer on its darovasertib (PKC) program, and with Amgen on its IDE397 (MAT2A) program. IDEAYA’s synthetic lethality platform integrates target and biomarker discovery, drug discovery, functional genomic and pharmacological validation, translational research, and opportunity expansion. The company has a proprietary library and data set resulting from its DECIPHER™ Dual CRISPR Synthetic Lethality library and is a member of the Broad Institute’s DepMap Consortium, enabling access to genome-wide screens of cell lines based on single CRISPR gene editing. IDEAYA’s translational biology platform includes capabilities for the discovery, validation, and clinical development of biomarkers. The company is actively pursuing the discovery and development of precision medicine therapeutics for oncogenic and synthetic lethality targets in solid tumors. IDEAYA’s clinical trials include studies on darovasertib for metastatic uveal melanoma and IDE397 for solid tumors harboring MTAP deletion. The company has an exclusive license with Novartis International Pharmaceutical Ltd. for developing and commercializing IDE196, a PKC inhibitor for cancers with GNAQ and GNA11 mutations. Furthermore, IDEAYA has established a strategic research collaboration with the Drug Discovery Unit at Cancer Research UK and the University of Manchester related to its PARG program and collaborates with Dr. Trey Ideker at UCSD on combinatorial CRISPR screens to identify next-generation synthetic lethality targets.